Merck
CN

ICH Q5A Regulatory Guidance Update

Stay up to date on the impact to biosafety testing

The International Council for Harmonization (ICH) published its original Q5A guidance in 1997. This global regulatory guidance outlines expectations regarding viral safety and viral clearance approaches for biotech products derived from human or animal cell lines.

Since the original publication, new therapeutic and vaccine modalities such as cell therapies and viral vectors have been developed. State-of-the-art detection technologies have emerged, and new manufacturing paradigms such as continuous manufacturing are also being adopted.

All these present unique challenges, and the regulation is now catching up with scientific development and industry expectations. This guideline revision is critical to today’s biologics landscape and viral safety.

The draft revision includes guidance on applications of molecular methods such as High Throughput sequencing (HTS) (i.e. Next Generation Sequencing (NGS)) and degenerate PCR (such as the Blazar® platform) for adventitious testing and viral clearance. It is confirmed that this will provide support for industry and regulators to assess the suitability of new methods in the context of viral safety.

Our regulatory experts are actively investigating changes to the ICH Q5A guidance and are hosting webinars as well as presentations helping biopharma companies to understand challenges and opportunities brought by the revision of the regulatory guideline.

Read White Paper

ICH Q5A(R2): What’s new and changing?

ICH Q5A Scope

Impacts to Biosafety Testing

Impacts to Viral Clearance

The ICH Q5A revision addressing viral safety of biotechnology products derived from cell lines of human or animal origin was recently published for public comment.

A key strategy for viral risk mitigation is through the testing of the product at appropriate steps during the manufacturing process.

Requirements for viral clearance mostly remain the same. Flexibility can be offered for platform processes to leverage prior knowledge with appropriate justification.

Request additional information

Related Resources

Webinar: Viral safety of biologics: What's changing with the ICH Q5A revision?
Webinar: PDA Virus Conference Follow Up: What to Expect with ICHQ5A (R2) for mAbs, CGT, and Beyond
White Paper: Regulatory Considerations for Implementation of Alternative Microbial Methods for Quality Control Testing

Related Services
Next Generation Sequencing
Our next-generation sequencing (NGS) biosafety testing services deliver deep insights into biologic therapeutics such as monoclonal antibodies, viral vectors, and novel vaccines, rapidly characterizing your process while identifying known and unknown agents with pinpoint precision and accuracy.
Blazar® Rapid Molecular Detection
Accelerate the biosafety testing of your biologic therapy by replacing traditional testing with our unique Blazar® platform featuring multiplex degenerate PCR.
Viral Clearance Testing
Viral Clearance studies are critical to the validation of downstream processes, ensuring viral clearance process steps are effective and reproducible in the biopharma manufacturing setting.
Related Applications
Monoclonal Antibody Manufacturing
Monoclonal antibody manufacturing is a highly templated approach used to produce mAb-based immunotherapies. Robust, scalable process solutions are required at every step to ensure high therapeutic concentration and process safety, while meeting speed-to-market and cost containment concerns.
Gene Therapy Manufacturing
Growing use of gene therapies is driving rapid innovation in an evolving global market. Manufacturers bringing new gene therapies to life face complex challenges, requiring an experienced partner capable of integrating vector manufacturing, testing, safety, process development, and regulatory compliance.
Antibody-Drug Conjugate (ADC) Manufacturing
Antibody-drug conjugation (ADC) technology uses monoclonal antibodies (mAbs) to deliver potent, highly active pharmaceutical ingredients (HPAPIs) to targeted cells. Learn about processes and areas of expertise required to advance your ADC to market.
Cell Therapy Manufacturing
Introducing a new cell therapy demands optimal performance in upstream and downstream processing, process development, testing, and manufacturing. World-class products and partners are critical to success, speeding advancement of therapeutics that are effective, safe, and affordable.
Vaccine Manufacturing
From early phase development, through downstream purification to large scale vaccine production: learn more about vaccine process development and application expertise.
Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?